Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, Cai-Hong, Boggon, Titus J., Li, Yiqun, Woo, Michele S., Greulich, Heidi, Meyerson, Matthew, Eck, Michael J.·2007·Cancer Cell
DOI 10.1016/j.ccr.2006.12.017

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy
    Peng Li, Hongmei Li, Wencai Yan, Yingjie Liu, Haihao Zhu, Yingcai Hong · 2025 · Frontiers in Immunology
  2. Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy
    Daniel Rosas, Jay Desai, Luis Estuardo Raez · 2026 · International Journal of Molecular Sciences
  3. Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology
    David E. Heppner, Monica R. MacDonald, Nader N. Nasief, Shilpa E. Naik, Sahba Cunningham · 2026 · ACS Bio & Med Chem Au
  4. Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
    Yong‐Jin Wu, Alyah F. Chmiel, Joanne J. Bronson · 2026 · Journal of Medicinal Chemistry
  5. Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer
    Vishnupriya Kanakaveti, P. Anoosha, Ramasamy Sakthivel, Suresh Kumar Rayala, M. Michael Gromiha · 2019 · Current Topics in Medicinal Chemistry
  6. Synthesis of novel pyrido[3,4‐d]pyrimidine‐thiazolidione‐1,2,4‐oxadiazoles as potent EGFR targeting anticancer agents
    Botla Durga Varaprasadu, Sharath Babu Haridasyam, Shiva Kumar Koppula · 2024 · Journal of Heterocyclic Chemistry
  7. Water‐Soluble Curcumin Derivatives Including Aza‐Crown Ether Macrocycles as Enhancers of Their Cytotoxic Activity
    Antonino Arenaza‐Corona, Paola Sánchez‐Portillo, Lucero González‐Sebastián, Arturo Sánchez‐Mora, Brian Monroy-Torres, Teresa Ramírez‐Ápan, Nicolás Puentes‐Díaz, Jorge Alí‐Torres, Víctor Barba, Viviana Reyes‐Márquez et al. · 2024 · Chemistry & Biodiversity
  8. Covalent Epidermal Growth Factor Receptor (EGFR) Inhibitors in Targeted Therapy of Drug-Resistant Non-Small Cell Lung Cancer (A Review)
    A. B. Shvetsov, Andrey Semenov · 2024 · Russian Journal of Bioorganic Chemistry
  9. Traditional Chinese Medicines as Anticancer Agents for Non-Small Cell Lung Cancer with EGFR Mutations: A Review
    Zhiying Wang, Zhixian Zhong, Wenxiao Yang, Yun Li, Ke Zhang, Yabin Gong, Lijing Jiao, Ling Xu · 2025 · Drug Design Development and Therapy
  10. Biomarkers for the targeted therapies of non-small cell lung cancer
    Antônio Rossi, Galetta · 2012 · Current Biomarker Findings
  11. Dynamics fingerprints of active conformers of epidermal growth factor receptor kinase
    German Patricio Barletta, Marcia Anahí Hasenahuer, Marı́a Silvina Fornasari, Gustavo D. Parisi, Sebastian Fernández-Alberti · 2018 · Journal of Computational Chemistry
  12. Synthesis, In Vitro Antiproliferative Activity, and In Silico Studies of New Anilinoquinazoline Derivatives as Potential AntitumorAgents
    Muhammad Kumayl Abdulwahab, Rashidi Dzul Keflee, Tan Ke Han, R. A. Ruslan, Kok Hoong Leong, Choon Han Heh, Azhar Ariffin · 2020 · Russian Journal of General Chemistry
  13. Evaluation of the Synthesized Novel Iridium (III) Complexes Against HeLa Cell Lines Through In-Silico, In-Vitro and DNA Nicking
    G. Sathya Priyadarshini, Aathi Muthusankar, Ramesh Subramani, Selvi Gopal · 2021 · Asian Pacific Journal of Cancer Prevention
  14. EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors
    Debasis Das · 2022 · Elsevier eBooks
  15. EGFR, NF-κB and noncoding RNAs in precision medicine
    Yanli Li, Xiaomin Liu, Zhongliang Ma · 2022 · Progress in molecular biology and translational science
  16. CRISPR-Based Fluorescent Reporter (CBFR) Assay for Sensitive, Specific, Inexpensive, and Visual Detection of a Specific EGFR Exon 19 Deletion in NSCLC
    Pouya Salehipour, Mojdeh Mahdiannasser, Ghazal Sedaghat Shayegan, Kimia Shankaie, Mina Hajifaraj Tabrizi, Majid Mojarrad, Mohammad Hossein Modarressi · 2022 · Molecular Biotechnology
  17. Experimental spectroscopic and quantum computational investigation and molecular docking analysis of N-benzyloxycarbonyl-l-serine – an anticancer agent
    A. Jeelani, S. Muthu, Fazilath Basha Asif, Ahmad Irfan, R Rajesh · 2023 · Spectroscopy Letters
  18. Rapid Rescoring and Refinement of Ligand–Receptor Complexes Using Replica Exchange Molecular Dynamics with a Monte Carlo Pose Reservoir
    Juan Alcantara, Kelley Chiu, John D. Bickel, Robert C. Rizzo, Carlos L. Simmerling · 2023 · Journal of Chemical Theory and Computation
  19. Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC
    Varsha Tripathi, Aishwarya Khare, Divyanshi Shukla, Shiv Bharadwaj, Nikhil Kirtipal, Vandana Ranjan · 2024 · International Immunopharmacology
  20. The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
    Fenneke Zwierenga, L. Zhang, Josef Melcr, Ed M. D. Schuuring, Bianca A. M. H. van Veggel, Adrianus Johannes de Langen, Harry J.M. Groen, Matthew R. Groves, Anthonie J. van der Wekken · 2024 · Lung Cancer
  21. Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR
    Duhita Mirikar, Nandini Banerjee, Kumar Prabhash, Rajiv Kumar, Vanita Naronha, Conjeevaram S. Pramesh, George Karimundackal, Amit Joshi, Swapnil Ulhas Rane, Ranjan Basak · 2025 · Scientific Reports
  22. Coexistence of three EGFR mutations in an NSCLC patient: A brief report
    Francesca Belardinilli, Angela Gradilone, Alain Jonathan Gelibter, Massimo Zani, Mario Alberto Occhipinti, Sergio Ferraro, Chiara Nicolazzo, Anna Coppa, Giuseppe Giannini · 2018 · The International Journal of Biological Markers
  23. In silico Identification of Peptide as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Treatment
    Shabrina Noor Imana, Eka Gunarti Ningsih, Usman Sumo Friend Tambunan · 2020 · Pakistan Journal of Biological Sciences
  24. Molekulardiagnostik zur Therapiestratifizierung des Lungenkarzinoms
    Lukas Carl Heukamp, Juergen Wolf, Reinhard Büttner · 2011 · Der Internist
  25. The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease
    Jonathan Lam, Stewart J. · 2012 · InTech eBooks
  26. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib
    Ramón González Manzano, E. Martinez-Navarro, Elena Eugenieva, Francisco José Fernández Morejón, José Farré, Antonio Brugarolas · 2008 · Clinical & Translational Oncology
  27. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors
    Kristen M. Kreamer, Debbie Riordan · 2015 · Clinical journal of oncology nursing
  28. Structural basis for EGFR transmembrane signaling and its implications in therapeutic development
    Li-Zhi Mi, ShaoWei GU, XingXing WANG · 2018 · Scientia Sinica Vitae
  29. Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib
    Ying Liu, Yun Du · 2021 · Technology in Cancer Research & Treatment
  30. VALORIZATION OF PERILLALDEHYDE MOLECULE CONTAINED IN THE ESSENTIAL OIL OF Ammodaucus Leucotrichus Coss. FROM THE SAHARAN ZONES OF MOROCCO
    Omayma Bouzekri, Sabah Elgamouz, Adib Ghaleb, Ali Amechrouq, Mostafa El Idrissi, M’barek Choukrad · 2022 · Journal of Microbiology Biotechnology and Food Sciences
  31. Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells
    Chawannuch Mudjupa, Sherif Abdelhamed, Alaa Refaat, Satoru Yokoyama, Ikuo Saiki, Opa Vajragupta · 2015 · Journal of Applied Biomedicine
  32. Kinase Inhibitors: Approved Drugs and Clinical Candidates
    Robert Hart Bradbury · 2010 · Burger's Medicinal Chemistry and Drug Discovery
  33. Kinase Inhibitors
    Peng Wu, Michael Givskov, Thomas E. Nielsen · 2017 · Methods and principles in medicinal chemistry
  34. Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers
    Ming-Tseh Lin, Gang Zheng, Erika F. Rodriguez, Li‐Hui Tseng, Vamsi Parini, Rena R. Xian, Ying S. Zou, Christopher D. Gocke, James R. Eshleman · 2021 · American Journal of Clinical Pathology
  35. Synthesis and Cytotoxic Activities of Novel Ether Conjugates of Dihydroartemisinin and Zerumbone: Evidenced by Integrating Network Pharmacology and In Vitro Assay
    Ngoc Hung Truong, Phi Hung Nguyen, Huu Nghi Do, Nguyen Xuan Ha, Thanh Vu, Hai Pham‐The, Hanh Trang Luu, Manh Cuong Nguyen, Van Chinh Luu · 2024 · Chemistry & Biodiversity
  36. Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study
    Jian Wang, Feiyang Yuan, Mahadevi Vitthal Kendre, Zhijin He, Shaowei Dong, Abhinandan Patil, Kalusing S. Padvi · 2025 · Frontiers in Oncology
  37. Molecular dynamics simulations reveal a strong binding capacity of colossolactone H to the EGFR inactive conformation
    Duc Toan Truong, Kiet Ho, Chinh Tam Thai, Do Thi Mai Dung, Minh Tho Nguyen, Thi Viet Bac Phung, Minh Tho Nguyen · 2025 · Physical Chemistry Chemical Physics
  38. Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity
    Mai S. El-Shoukrofy, May E. Amr, Tarek M. Okda, A.‐M. M. E. OMAR, Omaima M. Aboulwafa · 2025 · Bioorganic & Medicinal Chemistry
  39. Synthesis, characterization, molecular docking, and anticancer evaluation of new bis-1,2,3-triazole derivatives
    Fatih Çelik, Ali Osman Aydın, Halil İbrahim Güler, Yasemin Ünver, Ersan Bektaş · 2025 · Journal of Molecular Structure
  40. Development of Novel Indole–1,3,4-Oxadiazole Hybrids Targeting EGFR in Lung Cancer: Synthesis, Anticancer Evaluation, and Computational Study
    Ganesh Babu N. V. N. Kolukula, M. Raga Sudha, S. Subramanyam, Tejeswara Rao Allaka · 2025 · Russian Journal of Organic Chemistry
  41. Design, Synthesis and Biological Effects Studies of Novel EGFR Inhibitors Targeting Wild-Type and Mutant EGFR (EGFR-L858R and EGFR-L858R/T790M)
    Derya Osmani̇ye, Ümit Balıkçı, Berkant Kurban, Yusuf Özkay, Zafer Asım Kaplancıklı · 2026 · ACS Omega
  42. Bioisostere Identification by Determining the Amino Acid Binding Preferences of Common Chemical Fragments
    Tomohiro Sato, Noriaki Hashimoto, Teruki Honma · 2017 · Journal of Chemical Information and Modeling
  43. Evolution and Functional Divergence of the ERBB Receptor Family
    Shanshan Wu, Jeffrey Haltom, Wenyi Zhao, Jingwen Yang, Zhan Mei Zhou, Xun Gu · 2021 · Pharmacogenomics
  44. One-Pot Surface Modification of β-Cu 2 O NPs for Biocatalytic Performance against A-549 Lung Carcinoma Cell Lines through Docking Analysis
    Gulam Abbas, Gajanan Pandey, Kijay Bahadur Singh, Neelam Gautam · 2021 · ACS Omega · Retracted
  45. Mechanism of Synsepalum dulcificum Daniell. Inhibiting Lung Adenocarcinoma
    Qi Chen, Tingting Liu, Tuya Bai, Mengdi Zhang, Yuxia Hu, Jun Li, Fuhou Chang · 2022 · Evidence-based Complementary and Alternative Medicine
  46. Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1
    Kiyoaki Uryu, Yoshinori Imamura, Rai Shimoyama, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Makoto Hibino, Shigeto Horiuchi et al. · 2024 · Cancer Chemotherapy and Pharmacology
  47. Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers
    Yi Zeng, Chenyang Huang, Qiangqiang Hou, Wenhua Jiang, Jiaqi Cheng, Xiaoxing Wu · 2024 · Bioorganic Chemistry
  48. Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study
    Amrita Das, Mary A. Biggs, Hannah L. Hunt, Vida Mahabadi, Beatriz G. Goncalves, Chau Anh N. Phan, Ipsita A. Banerjee · 2024 · Molecular Diversity
  49. Dicentrine and its N-oxide derivatives induces apoptotic and necrotic cell death in prostate cancer cell lines
    Ranyelison S. Machado, Daniela C. Tristão, Natália Meneses Araújo, Elias Jorge Muniz Seif, Kayo Alexandre S. da Cruz, Mirian Galliote Morale, Ileana Gabriela Sanchez Rubio, João Henrique G. Lago, Rodrigo Esaki Tamura · 2025 · European Journal of Medicinal Chemistry Reports
  50. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer
    Ridhima Wadhwa, Keshav Raj Paudel, Shakti Dhar Shukla, Madhur D. Shastri, Gaurav Gupta, Hari Prasad Devkota, Mary Bebawy, Dinesh Kumar Chellappan, Philip M. Hansbro, Kamal Dua · 2021 · Springer eBooks
  51. Structure-function of EGFR kinase domain and its inhibitors
    Charles W. Eigenbrot · 2008 · Humana Press eBooks
  52. Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer
    Sourav Sikdar, Anisur Rahman Khuda‐Bukhsh · 2013 · TANG [HUMANITAS MEDICINE]
  53. Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean Anthony Fennell, Charles Swanton · 2012 · The EPMA Journal
  54. An Evolutionary General Purpose WebGIS to Disclose EGFR Mutations in Lung Cancer
    Domenico Aliotta, Pietro Buffa, Gennaro Iaccarino · 2008 · Lecture notes in computer science
  55. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
    Peng Hu, Daxiong Han, Runsheng Ruan, Li-Mou Zheng, Shiu-Huey Chou, Chi‐Meng Tzeng · 2016 · Oncotarget
  56. Medicinal Chemistry Case History: Osimertinib (AZD9291)
    Richard A. Ward, M. Raymond V. Finlay · 2016 · Elsevier eBooks
  57. Current Advances in Computational biology of Lung Cancer
    Purbasha Pati · 2022 · International Journal of Current Science Research and Review
  58. Virtual Screening and Molecular Docking Analysis of Degradation Products of Curcumin as Inhibitors of EGFR
    Swarita Gopal · 2022 · Journal of Computational Biophysics and Chemistry
  59. A Paradigm Shift in Experimental Biochemistry: A Priori Estimation of Physical Parameters of Biomolecules
    Kirill G. Kulikov, Tatiana Koshlan, A. P. Golovitsky · 2023 · Biophysical Reviews and Letters
  60. Synthesis, Spectroscopic Analysis, Molecular Docking, Molecular Dynamics Simulation of 5-(Adamantan-1-yl)-4-(3-Chlorophenyl)-2,4-Dihydro-3 H -1,2,4-Triazole-3-Thione, a Potential Anti-proliferative Agent
    Alaa S. Abdelrazeq, Hazem A. Ghabbour, Lamya Hamad Al-Wahaibi, Mohammed S. M. Abdelbaky, Santiago García‐Granda, Ali Abdel-Rahman El-Emam, Shilendra K. Pathak, Ruchi Srivastava, Anushree Maurya, Vikas K. Shukla et al. · 2023 · Polycyclic aromatic compounds
  61. Investigation of therapeutic modalities of G719X, an uncommon mutation in the EGFR gene in non-small cell lung cancer
    Hua Zheng, Yuan Jiao Gao, Zan Liu, Zhe Qian, Tongmei Zhang, Jie Li, Hongmei Zhang, Qunhui Wang, Fanbin Hu, Baolan Li · 2019 · Oncology and Translational Medicine
  62. scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers
    Peng Tian, Jie Zheng, Keying Qiao, Yuxiao Fan, Yue Xu, Tao Wu, Shuting Chen, Yinuo Zhang, Bingyue Zhang, Chiara Ambrogio et al. · 2024 · Advanced Science
  63. Receptor Tyrosine Kinases
    Kelly Karl, Taylor P. Light, Kalina A. Hristova · 2021 · Elsevier eBooks
  64. Predictive Tumor Biomarkers for EGFR Inhibitors
    Lucia Kim, Geoffrey Liu, Ming‐Sound Tsao · 2014 · Lung Cancer
  65. Tyrosine Kinase Inhibitors
    David J. Matthews, Mary E. Gerritsen · 2010 · Wiley eBooks
  66. Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing
    Younggwang Kim, Hyeong-Cheol Oh, Seung‐Ho Lee, Seokjoong Kim · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  67. DFT Calculation, ADME/T and Molecular Docking Approach of Methyl 2-oxo-1,2-dihydrofuro[3,4-d] pyrimidine-3(4H)carboxylate
    Gühergül Uluçam · 2024 · Journal of the Mexican Chemical Society
  68. A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells
    Lanxin Li, Chenyang Liu, Rui Wang, Xiaolin Yang, Xiangkai Wei, Chunhong Chu, Guoliang Zhang, Chenxue Liu, Wenrui Cui, Huixia Xu et al. · 2024 · Scientific Reports
  69. Method development for potential drug target identification and drug discovery
    Daohong Gong, Jianxin Tang, Baoli Wang, Sutong Xiang, Ziyan Feng, Shiliang Li, Honglin Li · 2025 · Scientia Sinica Chimica
  70. Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer
    Li-Hua Wu, Ruocheng Yu, Minghui Yao, Md. Matiur Rahaman, Zhaoyuan Fang · 2025 · Journal of Bioinformatics and Computational Biology
  71. A network pharmacology analysis of curcumin in the treatment of oral submucous fibrosis
    Fangping Deng, Shuxin Fu, Dandan Li, Shuo Qi, Hong Zou · 2025 · Computational Biology and Chemistry
  72. Identification of novel lead molecules against the EGFR kinase domain using structure-based virtual screening, molecular docking, and molecular dynamics simulations
    Mythreyi Jannu, Umakanth Naik Vankadoth, Amineni Umamaheswari, Rajeswari Jinka · 2025 · Journal of Receptors and Signal Transduction
  73. Hydrazone-linked isatin-pyridine hybrids for EGFR inhibition: Insights from density functional and molecular docking analyses
    Shilendra K. Pathak, Zohra Siddiqui, Anushree Maurya, Mamta Pal, Raj Shukla, Ruchi Srivastava, V K Shukla V K Shukla, Onkar Prasad, Leena Sinha · 2025 · Journal of Molecular Structure
  74. A case study of the application of AI to early stage drug discovery
    Abbi Abdel‐Rehim, Larisa Soldatova, Ross D. King · 2025 · Scientific Reports
  75. Anticancer potential of Dendrocnide meyeniana through phytochemical profiling, ADMET analysis, molecular docking, and in silico cytotoxicity evaluation
    Edlyn E. Pooten, Khristina Judan Cruz, Evaristo A. Abella, Anna Karen Carrasco Laserna, Abul Bashar Mir Md. Khademul Islam, Kozo Watanabe · 2025 · Scientific Reports
  76. TARGETED SEARCH FOR INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR BY MOLECULAR DOCKING AND MOLECULAR DYNAMICS METHODS IN A SERIES OF HYDROXYPHENYL DERIVATIVES OF 4-OXOPYRIMIDINEBENZSULFONAMIDE
    Oleg Ivanovich Kit, Ivan P. Kodonidi, Alexander A. Glushko, Elena Mikhaylovna Frantsiyants, Denis Stanislavovich Anenko, Irina V. Kaplieva, A. Chiriapkin, Polina Sergeevna Kachesova · 2025 · INDIAN DRUGS
  77. Disruption of the intramolecular interaction between human lung cancer-related EGFR kinase domain and carboxy-terminal tail by intra-Tyr1016 phosphorylation or extra-peptidic competitors
    Tian-Chang Zhen, Yan Wu, Xian-Qi Zhang · 2026 · Journal of Molecular Modeling
  78. Design, synthesis, characterization, and biological evaluation of novel iminocoumarin derivatives: In vitro anticancer activity against NSCLC and ex vivo NLRP3 inflammasome inhibition supported by docking and ADMET studies
    Massinissa Baymout, Amal Rabahi, Louisa Béchohra, Sonia Missiroli, Kenza Saida Ouandjeli, Fouzia Touahra, Paolo Pinton, Carlotta Giorgi · 2026 · Journal of Molecular Structure
  79. Unlocking the therapeutic potential of Origanum majorana through GC-MS and computational analysis to identify EGFR inhibitors for breast cancer
    Hamad Zaid Alkhathlan, Eman Alshareef, Tanmoy Dutta, Shatha Ibrahim Alaqeel, Fouzia Latif, Merajuddin Khan · 2026 · Scientific Reports
  80. Estimating the EGFR Ligand‐Binding Affinity and Pose via Molecular Docking Simulations
    Hoang Anh Nguyen, Van V. Vu, Dương Tuấn Quang, Sơn Tùng Ngô · 2026 · ChemistrySelect
  81. Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors
    Ximeng Liu, Moses H. Stamboulian, Maxime Borgeaud, Erjia Zhu, Caroline M. Weipert, Nicole Zhang, Monique B. Nilsson, Kaiwen Wang, Lingzhi Hong, Jinghao Wang et al. · 2026 · Journal of Thoracic Oncology
  82. Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
    Rita Khoury, Chris Raffoul, Colette Hanna, Khalil Saleh, Annoir Shayya, Meriana Nahouli, Hady Ghanem · 2026 · International Journal of Molecular Sciences
  83. Structure-guided discovery and evaluation of an EGFR L858R-targeting peptide with antiproliferative activity against ovarian cancer cells
    Yinxing Zhu, Hanying Wu, Xiaohao Liu, Rui Li, Min Jiang · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
  84. Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
    Yi Chen, Qiu-pei Liu, Si-jie Yang, Jian Ding, Xiao-Yun Lu, Hua Xie · 2026 · Acta Pharmacologica Sinica
  85. Chemical Profiles, Pharmacological Insights, and In Silico Studies of Antidesma montanum Blume: An Experimental and Computer‐Aided Approach
    Naureen Banu, Najmul Alam, Sadia Farid Jhuma, Mohammad Nazmul Islam, Shady A. Alghazali, Md Abdul Awal, Sanjida Islam, Hafsa Siddiqua, Shafinaz Nur, Md. Sohel Rana · 2026 · eFood
  86. A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases
    Nader N. Nasief, Kishan B. Patel, Blessing C. Ogboo, David E. Heppner · 2026 · Journal of Medicinal Chemistry
  87. Photonic cancer therapy: modulating cellular metabolism with light
    Isabel Coutinho, Manuel Correia, Viruthachalam Thiagarajan, Gnana Prakash Gajula, Steffen Bjørn Petersen, Maria Teresa Neves‐Petersen · 2013 · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
  88. Acid–base chemistry of frustrated water at protein interfaces
    Ariel Fernández · 2015 · FEBS Letters
  89. Regulation of Cell Proliferation by Receptor Tyrosine Protein Kinases
    IJsbrand M. Kramer · 2015 · Elsevier eBooks
  90. Synthesis and Anti-proliferative Activity of Substituted-Anilinoquinazolines and Its Relation to EGFR Inhibition
    Dalal A. Abou El Ella, K. Saleh, M. Hassan, Nehal Aly Hamdy, Moustafa E. El‐Araby, Khaled A. M. Abouzid · 2012 · Arzneimittelforschung
  91. Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells
    Ewa Marcinkowska, Elżbieta Gocek · 2016 · Resistance to targeted anti-cancer therapeutics
  92. Aptamer and aptamer pharmaceuticals
    Ting Zheng, Ziyue Ma, Quan Du · 2018 · Scientia Sinica Chimica
  93. What do we know about the molecular and biological features of EGFR in glioblastomas and non-small cell lung cancer?
    Lali M. Kogoniya, Marina S. Gubenko, Turna Ashkhatcava · 2022 · Meditsinskiy sovet = Medical Council
  94. Computational characterization of homologous ligands binding to a deep hydrophobic pocket in Shigella flexneri pilot protein MxiM
    Shun Ni Zhu · 2022 · Proteins Structure Function and Bioinformatics
  95. Topological effects in ultrafast photoinduced processes between flurbiprofen and tryptophan in linked dyads and within human serum albumin
    Lorena Tamarit, Laura García-Gabarda, M. Consuelo Jiménez, Miguel Angel Miranda, Ignacio Vayá · 2023 · Physical Chemistry Chemical Physics
  96. A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology
    Justin J. Kim, Ilse K. Schaeffner, David E. Heppner, Ciric To, Pasi Antero Janne, Tyler S. Beyett, Michael J. Eck · 2023 · Molecular Pharmacology
  97. Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study
    Hannah L. Hunt, Beatriz G. Goncalves, Mary A. Biggs, Mia I. Rico, Molly E. Murray, Charlotta G. Lebedenko, Ipsita A. Banerjee · 2024 · Molecular Diversity
  98. Novel bibenzyl compound Ae exhibits anti-agiogenic activity in HUVECs in vitro and zebrafish in vivo
    Li Guan, Shengjie Zhang, Pengfei Song, Yanxin Xia, Xinle Zheng, Weize Li · 2024 · Bioorganic & Medicinal Chemistry
  99. Network pharmacology study on the mechanism of Curcumae Rhizoma in the treatment of non-small cell lung cancer
    Zhirui Yang, Mingquan Wu, Xin Zhou, Jin Cai Luo, Yi Liu, Lin Li · 2025 · Medicine
  100. Predicting Probable Ligands to Inhibit HER2-EGFR in Gastric Cancer
    Bioinformatics, Jamia Hamdard, India, Mahboubeh Mehmankhah, S Ramachandran, M. Afshar Alam · 2014 · IOSR Journal of Pharmacy and Biological Sciences